Ensign Group (ENSG)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Research Workspace
Put ENSG beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Revenue reaches about $5.83 billion in FY 2026: FY26 revenue guidance mid $5.90B vs $5.83B target.
View ThesisRanks among the strongest in its industry on quality — around the top 23%.
View QualityManagement screens strong on earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskEnsign Group's growth has to keep compounding to justify the price. Revenue grew 17% year over year, and the last quarter beat expectations. It trades at 24× P/E versus a peer median of 23×. The price reflects less growth than forecasted, indicating modest expectations. If ENSG cuts guidance after recently raising it, that would damage credibility. Peer multiples imply a price about 4% above where it trades. This read is provisional; the thesis is on watch.
Trailing returns as of 2026-09-04. ENSG is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering ENSG (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare ENSG with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ENSG Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Facilities — fair value, gap to price, and forward P/E.
Compare the value case
Put ENSG next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Securities law investigation may impact investor confidence.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Investigation could lead to legal issues affecting operations.
Threatens: Increase revenue growth
Compliance concerns may hinder revenue growth.
Threatens: Increase revenue growth
Allegations of compliance issues could impact revenue.
Threatens: Increase revenue growth
Short seller report raises concerns about revenue stability.
Advances: Increase revenue growth
Strong results indicate robust revenue growth.